THQ - abrdn Healthcare Opportunities Fund

What this means for you

None of the investors we follow has reported owning 5% or more of this fund. That is the normal state for most closed-end funds.

Nothing is required of you. If that changes, the notice appears here within a day of being filed with the regulator.

Email me if this changes

What happened, and when

Nothing on file yet. No large investor has reported a stake in this fund, and the fund has not announced a buy-back, a vote or a closing.

About this fund

• Run by abrdn Inc. As of Sept 30, 2025, from the fund's yearly report. Original document →
• Size: about $826 million of holdings, as of June 30, 2026. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Borrowing: the fund borrows about 22% on top of its own money, as of June 30, 2026. Borrowed money makes gains and losses bigger. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Costs: 1.3% a year in management fees; 3% a year in total, including interest on borrowed money. Fiscal year ended Sept 30, 2025. As of Sept 30, 2025, from the fund's yearly report. Original document →
  Among the 7 funds we follow that invest in healthcare companies, 5 charge a lower management fee and 5 charge less in total, at their last yearly reports. Both numbers are measured against the fund's own money, not the money it borrows on top, so a fund that borrows more shows higher costs on both counts.
• Payouts: last fiscal year (ended Sept 30, 2025) the fund paid $2.16 a share. $0.10 of that was income; $2.06 was your own money back, not income. Most funds announce their monthly or quarterly payout on their own website, not in a filing with the regulator, so a cut or a raise there does not show up here until the next yearly report. A few funds do file a notice about a fixed payout; those appear under What happened, and when. As of Sept 30, 2025, from the fund's annual report. Original document →
• Value of holdings per share at the last fiscal year end (Sept 30, 2025): $17.89. The shares traded at $17.29, about 3.4% below that. As of Sept 30, 2025, from the fund's yearly report. Original document →
• How the holdings did: up 14.8% over the last three months we have (April-June 2026), before the share price is taken into account. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• First reported to the regulator in 2014.

How this has changed

• Payouts per share: $2.16 in the fiscal year ended Sept 30, 2025; $1.89 in the year ended Sept 30, 2024; $1.35 in the year ended Sept 30, 2023.As of Sept 30, 2025, from the fund's annual report. Original document →
• Of that, your own money back rather than income: $2.06 in the year ended Sept 30, 2025; $0.80 in the year ended Sept 30, 2024; none in the year ended Sept 30, 2023.As of Sept 30, 2025, from the fund's annual report. Original document →
• Costs, including interest on borrowed money: 3.02% a year in the fiscal year ended Sept 30, 2025; 3.1% a year in the year ended Sept 30, 2024; 2.95% a year in the year ended Sept 30, 2023.As of Sept 30, 2025, from the fund's annual report. Original document →
• Size of the holdings: about $741 million at Sept 30, 2025; $944 million at Sept 30, 2024; $833 million at Sept 30, 2023. From the fund's quarterly holdings reports. Original documents: Sept 30, 2025 →, Sept 30, 2024 →, Sept 30, 2023 →.
• Borrowing: about 24% on top of its own money at Sept 30, 2025; 20% at Sept 30, 2024; 22% at Sept 30, 2023. From the fund's quarterly holdings reports. Original documents: Sept 30, 2025 →, Sept 30, 2024 →, Sept 30, 2023 →.
• The fund had about 41.4 million shares at Sept 30, 2025, about the same as at Sept 30, 2023.As of Sept 30, 2025, from the fund's annual report. Original document →

What these lines mean: a payout that is your own money back, what a fund costs, borrowing.

What a holder made

• The year ended Sept 30, 2025: the shares returned -12.3%, counting payouts; the holdings -12.2%. The holdings figure is what the fund's investments earned, before the share price is taken into account. As of Sept 30, 2025, from the fund's annual report. Original document →
• The year ended Sept 30, 2024: the shares returned +43%, counting payouts; the holdings +24.7%. As of Sept 30, 2024, from the fund's annual report. Original document →
• The year ended Sept 30, 2023: the shares returned +0.6%, counting payouts; the holdings +6.9%. As of Sept 30, 2023, from the fund's annual report. Original document →
• The year ended Sept 30, 2022: the shares returned -14.8%, counting payouts; the holdings -9.1%. As of Sept 30, 2022, from the fund's annual report. Original document →
• The year ended Sept 30, 2021: the shares returned +33.3%, counting payouts; the holdings +24.1%. As of Sept 30, 2021, from the fund's annual report. Original document →
• Those five years together: the shares returned +43.1%. $10,000 of shares bought at the start (Oct 1, 2020) would have become about $14,300 by Sept 30, 2025, with every payout counted, before tax. As of Sept 30, 2025, from the fund's annual report. Original document →
• The holdings over the last twelve months we have, to June 30, 2026: +14.8%. The quarterly reports carry no share price, so this is the holdings alone. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Of the 7 funds that invest in healthcare companies with a fiscal year ending within six months of this one, 6 reported a higher share return for that year and 0 a lower one. As of Sept 30, 2025, from the fund's annual report. Original document →
• A past year says nothing about the next one. All figures are the fund's own, from its reports to the regulator.

Why the shares and the holdings can differ: the gap between price and value. Why payouts count: a payout that is your own money back.

What the fund holds

Mostly shares (83%), the rest bonds, preferred shares and cash and short-term holdings. About 90% issued in the U.S.

The fund also sells options on its holdings to raise income.

1. VeraDermics - 9.3%
2. UnitedHealth Group - 6.1%
3. Abbott Laboratories - 4.8%
4. Merck & - 4.4%
5. Medtronic PLC - 4.3%
6. Thermo Fisher Scientific - 4.2%
7. Intuitive Surgical - 3.4%
8. CVS Health - 3.3%
9. Danaher - 3.2%
10. Oruka Therapeutics - 2.9%

As of June 30, 2026, from the fund's quarterly holdings report. Original document →